Serologic Follow-up of Middle East Respiratory Syndrome Coronavirus Cases and Contacts-Abu Dhabi, United Arab Emirates.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Child
Child, Preschool
Coronavirus Infections
/ epidemiology
Disease Transmission, Infectious
Enzyme-Linked Immunosorbent Assay
Family Health
Female
Fluorescent Antibody Technique, Indirect
Humans
Infant
Infant, Newborn
Male
Middle Aged
Middle East Respiratory Syndrome Coronavirus
/ immunology
Risk Factors
Seroepidemiologic Studies
United Arab Emirates
/ epidemiology
Young Adult
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
18 01 2019
18 01 2019
Historique:
received:
08
02
2018
accepted:
12
06
2018
pubmed:
16
6
2018
medline:
7
3
2020
entrez:
16
6
2018
Statut:
ppublish
Résumé
Although there is evidence of person-to-person transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in household and healthcare settings, more data are needed to describe and better understand the risk factors and transmission routes in both settings, as well as the extent to which disease severity affects transmission. A seroepidemiological investigation was conducted among MERS-CoV case patients (cases) and their household contacts to investigate transmission risk in Abu Dhabi, United Arab Emirates. Cases diagnosed between 1 January 2013 and 9 May 2014 and their household contacts were approached for enrollment. Demographic, clinical, and exposure history data were collected. Sera were screened by MERS-CoV nucleocapsid protein enzyme-linked immunosorbent assay and indirect immunofluorescence, with results confirmed by microneutralization assay. Thirty-one of 34 (91%) case patients were asymptomatic or mildly symptomatic and did not require oxygen during hospitalization. MERS-CoV antibodies were detected in 13 of 24 (54%) case patients with available sera, including 1 severely symptomatic, 9 mildly symptomatic, and 3 asymptomatic case patients. No serologic evidence of MERS-CoV transmission was found among 105 household contacts with available sera. Transmission of MERS-CoV was not documented in this investigation of mostly asymptomatic and mildly symptomatic cases and their household contacts. These results have implications for clinical management of cases and formulation of isolation policies to reduce the risk of transmission.
Sections du résumé
Background
Although there is evidence of person-to-person transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in household and healthcare settings, more data are needed to describe and better understand the risk factors and transmission routes in both settings, as well as the extent to which disease severity affects transmission.
Methods
A seroepidemiological investigation was conducted among MERS-CoV case patients (cases) and their household contacts to investigate transmission risk in Abu Dhabi, United Arab Emirates. Cases diagnosed between 1 January 2013 and 9 May 2014 and their household contacts were approached for enrollment. Demographic, clinical, and exposure history data were collected. Sera were screened by MERS-CoV nucleocapsid protein enzyme-linked immunosorbent assay and indirect immunofluorescence, with results confirmed by microneutralization assay.
Results
Thirty-one of 34 (91%) case patients were asymptomatic or mildly symptomatic and did not require oxygen during hospitalization. MERS-CoV antibodies were detected in 13 of 24 (54%) case patients with available sera, including 1 severely symptomatic, 9 mildly symptomatic, and 3 asymptomatic case patients. No serologic evidence of MERS-CoV transmission was found among 105 household contacts with available sera.
Conclusions
Transmission of MERS-CoV was not documented in this investigation of mostly asymptomatic and mildly symptomatic cases and their household contacts. These results have implications for clinical management of cases and formulation of isolation policies to reduce the risk of transmission.
Identifiants
pubmed: 29905769
pii: 5037289
doi: 10.1093/cid/ciy503
pmc: PMC7108211
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-418Références
Emerg Infect Dis. 2016 Apr;22(4):647-56
pubmed: 26981708
Emerg Infect Dis. 2016 Jun;22(6):
pubmed: 27192543
Sci Rep. 2016 May 05;6:25359
pubmed: 27146253
N Engl J Med. 2014 Aug 28;371(9):828-35
pubmed: 25162889
Emerg Infect Dis. 2016 Jul;22(7):1162-8
pubmed: 27314227
Diagn Microbiol Infect Dis. 2017 Oct;89(2):106-111
pubmed: 28821364
Emerg Infect Dis. 2016 Aug;22(8):1395-402
pubmed: 27191038
Wkly Epidemiol Rec. 2015 May 15;90(20):245-50
pubmed: 25980038
Ann Intern Med. 2014 Mar 18;160(6):389-97
pubmed: 24474051
Emerg Infect Dis. 2017 Jul;23(7):1079-1084
pubmed: 28585916
N Engl J Med. 2015 Feb 26;372(9):846-54
pubmed: 25714162
Emerg Infect Dis. 2015 Dec;21(12):2186-9
pubmed: 26583829
Clin Infect Dis. 2014 Nov 1;59(9):1225-33
pubmed: 24829216
Emerg Infect Dis. 2016 Oct;22(10):1824-6
pubmed: 27332149
N Engl J Med. 2013 Jun 27;368(26):2487-94
pubmed: 23718156
Emerg Infect Dis. 2014 Dec;20(12):2148-51
pubmed: 25418612
Clin Infect Dis. 2016 Feb 15;62(4):477-483
pubmed: 26565003
Clin Infect Dis. 2016 Dec 10;64(5):551-557
pubmed: 27940937
N Engl J Med. 2017 Feb 9;376(6):584-594
pubmed: 28177862
Emerg Infect Dis. 2016 Jan;22(1):49-55
pubmed: 26692185
Int J Infect Dis. 2014 Dec;29:301-6
pubmed: 25303830
Emerg Infect Dis. 2016 Nov;22(11):1915-1920
pubmed: 27767011
Clin Infect Dis. 2015 Mar 15;60(6):973-4
pubmed: 25516193
N Engl J Med. 2013 Aug 1;369(5):407-16
pubmed: 23782161